Nektar Therapeutics (NKTR) Gross Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Gross Margin of 29.09% for Q1 2026, up 9410.0% year-over-year from 0.31% in Q1 2025, and down 70.91% quarter-over-quarter from 100.0% in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Gross Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Gross Margin history runs 17 years deep, the most recent figure standing at 29.09% for Q1 2026.
- In Q1 2026, Gross Margin rose 9410.0% year-over-year to 29.09%; the TTM figure through Mar 2026 stood at 67.65% (up 3508.0% YoY), while the FY2025 annual figure was 100.0%, up 4272.0% from the prior year.
- Gross Margin for Q1 2026 stood at 29.09%, down from 100.0% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q2 2025, with the low at 65.01% in Q1 2025.
- The 5-year median for Gross Margin is 55.78% (2023), against an average of 53.43%.
- The sharpest annual moves came in 2025 and 2026: Gross Margin sank 11323 bps in 2025, then surged 9410 bps in 2026.
- Nektar Therapeutics' Gross Margin stood at 71.7% in 2022, then declined by 22 bps to 55.78% in 2023, then slumped by 40 bps to 33.72% in 2024, then surged by 197 bps to 100.0% in 2025, then slumped by 71 bps to 29.09% in 2026.
- Business Quant data shows NKTR's Gross Margin at 29.09% in Q1 2026, 100.0% in Q4 2025, and 12.66% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | 29.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.97% |
| Mar 31, 2026 | 29.09% |
| Dec 31, 2025 | 68.61% |
| Sep 30, 2025 | 12.66% |
| Jun 30, 2025 | 7.62% |
| Mar 31, 2025 | -65.01% |
| Dec 31, 2024 | 70.51% |
| Sep 30, 2024 | 54.35% |
| Jun 30, 2024 | 52.22% |
| Mar 31, 2024 | 48.22% |
| Dec 31, 2023 | 55.78% |
| Sep 30, 2023 | 48.51% |
| Jun 30, 2023 | 65.88% |
| Mar 31, 2023 | 67.31% |
| Dec 31, 2022 | 71.70% |
| Sep 30, 2022 | 78.95% |
| Jun 30, 2022 | 76.30% |
| Mar 31, 2022 | 78.59% |
| Dec 31, 2021 | 75.36% |
| Sep 30, 2021 | 78.69% |